Curetopia
CURES
Evaluation Score
Overall rating on a scale of 0-10
Dimension Breakdown
AI Analysis
Comprehensive evaluation of the token
Curetopia (CURES) is a decentralized science (DeSci) BioDAO on Solana focused on rare disease drug repurposing under a Swiss Verein structure. Across all evaluated sections, the project exhibits early-stage development and significant structural risks. On the positive side, Team and Governance (5.5/10) reflects a publicly known founder (Ethan Perlstein) and successful capital formation via a $1.77 million Bio Protocol Launchpad raise in March 2025. However, the project scores poorly across technical and market fundamentals: Active Development (2.5/10) suffers from an absence of public code repositories and verifiable dated milestones; Community Support (3.5/10) exhibits low verifiable engagement data; Tokenomics (4.0/10) lacks full transparency regarding vesting and unverified supply schedules with potential dilution (39.3M circulating out of 100M total); Market and Use Case (2.5/10) is constrained by micro-cap valuation ($376K-$455K) and thin daily trading volume ($4.6K-$7.4K); and Security and Audit History (3.0/10) highlights an unaudited Solana smart contract, although no security exploits, delistings, or regulatory actions were identified. No qualifying red-flag events were established.
Development Activity
Code updates and developer engagement
Community Support
Social media presence and community engagement
Tokenomics
Supply, distribution, and utility
Market & Use Case
Value proposition and competitive landscape
Team & Governance
Team background and project governance
Security & Audits
Security history and audit status
About Curetopia (CURES)
Curetopia (CURES) is a decentralized science (DeSci) biotechnology decentralized autonomous organization (BioDAO) operating on the Solana blockchain. Structured as a Swiss Verein non-profit based in Zug, Switzerland, the organization was founded and is led by CEO Ethan Perlstein. The project's primary focus is funding and coordinating rare disease research and drug-repurposing initiatives, including self-reported programs such as "Project 001" for AARS2-related leukoencephalopathy. In March 2025, Curetopia raised approximately $1.77 million from over 1,000 contributors via a community launch on the Bio Protocol Launchpad.
The CURES token is designed for DAO governance and research participation incentives. Token holders can participate in organizational governance proposals through platforms like Commonwealth and Snapshot. The project also implements a model intended to reward patients and participants for contributing biospecimens and clinical data with CURES tokens. Out of a total supply of 100 million tokens, approximately 39.3 million are in circulation. The tokenomics structure does not include token burn mechanisms, and comprehensive vesting schedules and specific allocation percentages are not fully detailed in public documentation.
Curetopia faces several operational and market risks. The project trades as a micro-cap asset with constrained daily trading volume, presenting liquidity challenges alongside dilution risk from the uncirculated token supply. On the technical and security side, Curetopia's Solana smart contract has no record of a completed third-party security audit, and the organization lacks public code repositories and verifiable dated development milestones. Additionally, execution remains subject to centralization risks around a narrow core team, though no security exploits, regulatory actions, or exchange delistings have been recorded.